Viamet Pharmaceuticals Secures $12,000,014 New Funding
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=b7706a63-03cb-4774-9eee-eeac00bc0557 - Date
9/29/2016 - Company Name
Viamet Pharmaceuticals - Mailing Address
4505 Emperor Blvd. Durham, NC 27703 USA - Company Description
Viamet Pharmaceuticals discovers and develops best-in-class inhibitors of validated metalloenzymes via an innovative and proprietary metal-binding approach, our Metallophile Technology. - Website
http://www.viamet.com - Transaction Type
Venture Equity - Transaction Amount
$12,000,014 - Transaction Round
Undisclosed - Proceeds Purposes
Proceeds purposes were not disclosed. 12 investors participated in the offering. The amount may include options, warrants or other securities. Contact technology company for investment details, if applicable. Not an offer or solicitation for the sale of securities or debt. SEC regulatory filing. - M&A Terms
- Venture Investor
Undisclosed
